Market Overview

UPDATE: Bank of America Raises PT on MannKind Corporation Following Physician Survey

Related MNKD
10 Biotech Stories You Might've Missed This Week
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3
MannKind: FDA Delays Afrezza Decision by Three Months (Fox Business)

In a report published Wednesday, Bank of America analyst Steve Byrne reiterated a Buy rating on MannKind Corporation (NASDAQ: MNKD), and raised the price target from $3.00 to $5.00.

In the report, Byrne noted, “We commissioned a survey of 75 primary care physicians (PCPs) to assess the market opportunity for MNKD's inhaled insulin candidate Afrezza in both type 1 and type 2 diabetes patients. Results indicated meaningful use within a year of approval. We raised our peak share estimate for in the prandial insulin market to 4% (from 2%) and raised our peak share for combo use with oral drugs to 4% (from 3%). This raised our risk adj. peak US Afrezza sales est. to $2.25bn from $1.5bn and our DCF-derived PO to $5 (from $3). We model significantly lower penetration than our survey indicated, as physicians typically overestimate clinical use. We could see further upside pending the significance of the phase 3 results.”

MannKind Corporation closed on Tuesday at $3.33.

Latest Ratings for MNKD

Oct 2014Goldman SachsInitiates Coverage onNeutral
Aug 2014JefferiesInitiates Coverage onBuy
Jul 2014MLVDowngradesBuyHold

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Analyst Ratings


Related Articles (MNKD)

Around the Web, We're Loving...

Get Benzinga's Newsletters